{"classes":[{"categories":[{"measurements":[{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"393.0"},{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"393.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"DOR for a given participant is defined as the number of days from the date of that participant's first documented response (Partial Response \\[PR\\] or better) to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant with a documented response did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants positive for t(11;14) translocation who received at least 1 dose of study drug (venetoclax 400 mg, pomalidomide 4 mg, and dexamethasone 40 mg)","id":"OG000","title":"Participants Positive for t(11;14) Translocation"},{"description":"Participants negative for t(11;14) translocation who received at least 1 dose of study drug (venetoclax 400 mg, pomalidomide 4 mg, and dexamethasone 40 mg)","id":"OG001","title":"Participants Negative for t(11;14) Translocation"},{"description":"Participants who received at least 1 dose of study drug (venetoclax 400 mg, pomalidomide 4 mg, and dexamethasone 40 mg)","id":"OG002","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set: participants who received at least 1 dose of study drug (venetoclax 400 mg, pomalidomide 4 mg, and dexamethasone 40 mg) and had disease progression or death due to multiple myeloma","reportingStatus":"POSTED","timeFrame":"Approximately 15 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"days"}